When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study.

Purpose: To study the safety of resuming antitumor therapy in tumor patients infected with COVID-19.

Methods: We collected the clinical information of patients with tumors who were infected with COVID-19 and resume antitumor therapy between December 2022 and June 2023. Information about antitumor therapy, COVID-19-related symptoms, laboratory tests, antitumor therapy-related adverse events (AEs), and re-infection with COVID-19 were recorded.

Intermittent fasting for glycemic control in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.

Objective: to systematically evaluate the efficacy and safety of Intermittent Fasting (IF) in patients with type 2 diabetes (T2DM).

Method: randomized controlled trials (RCTs) on the efficacy of IF intervention in T2DM were systematically searched from PubMed, The Cochrane Library, Web of Science, MEDLINE and CNKI, and retrieval time was set from database onset to September 2024. A meta-analysis was performed using the RevMan 5.